Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.72 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377465 | 0.85 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL13483184 | 0.84 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL4285260 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| Sergliflozin A SCHEMBL23436839 | 0.84 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Sergliflozin A SCHEMBL2574820 | 0.84 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Sergliflozin A SCHEMBL4361463 | 0.84 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL13483183 | 0.82 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL2575949 | 0.81 | SLC5A2 (0.74) | SLC5A2SLC5A1 | |
| SCHEMBL28713870 | 0.81 | SLC5A2 (0.74) | SLC5A2SLC5A1 | |
| SCHEMBL2574895 | 0.79 | SLC5A2 (0.79) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | GPR119, NPR3, SLC5A2 | SLC5A2 3/4885SLC5A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.